JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

A

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

A

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

A

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

A

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

A

133.74

+0.46%↑

Search

CRISPR Therapeutics AG

Închisă

SectorSănătate

50.04 -6.08

Rezumat

Modificarea prețului

24h

Curent

Minim

49.66

Maxim

53.68

Indicatori cheie

By Trading Economics

Venit

102M

-106M

Vânzări

-3K

889K

Marjă de profit

-11,973.116

Angajați

393

EBITDA

101M

-101M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+30.52% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-428M

5.2B

Deschiderea anterioară

56.12

Închiderea anterioară

50.04

Sentimentul știrilor

By Acuity

100%

0%

331 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 ian. 2026, 22:31 UTC

Câștiguri

KLA Posts Higher 2Q Profit On Product and Services Sales Growth

29 ian. 2026, 22:05 UTC

Câștiguri

Stryker Logs Higher 4Q Profit On Sales Gains

29 ian. 2026, 21:54 UTC

Câștiguri

Visa 1Q Sales Climb on Strong Holiday Shopping -- Update

29 ian. 2026, 21:36 UTC

Câștiguri

Visa 1Q Sales Climb on Strong Holiday Shopping

29 ian. 2026, 23:57 UTC

Achiziții, Fuziuni, Preluări

Aluminum Corp. of China: to Hold 67% of Joint Venture With Rio Tinto

29 ian. 2026, 23:56 UTC

Achiziții, Fuziuni, Preluări

Aluminum Corp. of China: Deal Valued at Roughly BRL4.69 Billion

29 ian. 2026, 23:53 UTC

Achiziții, Fuziuni, Preluări

Aluminum Corp. of China Says It, Rio Tinto Propose to Buy 69% Stake in Companhia Brasileira de Aluminio S.A.

29 ian. 2026, 23:51 UTC

Câștiguri

Correction to Intel Earnings Article on Jan. 22 -- WSJ

29 ian. 2026, 23:49 UTC

Market Talk

Nikkei May Decline After Wall Street Tech Selloffs -- Market Talk

29 ian. 2026, 23:49 UTC

Market Talk

Gold Rises Amid Ongoing Iran Tensions -- Market Talk

29 ian. 2026, 23:47 UTC

Market Talk

Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

29 ian. 2026, 23:35 UTC

Câștiguri

Apple Posts Blowout iPhone Sales on Surging China Demand -- 2nd Update

29 ian. 2026, 23:32 UTC

Market Talk

REA's 1H Result Could Jolt Share Price More Than Usual -- Market Talk

29 ian. 2026, 23:32 UTC

Market Talk

Global Equities Roundup: Market Talk

29 ian. 2026, 23:15 UTC

Market Talk
Câștiguri

Visa Says High Earners Still Lead Spending Growth -- Market Talk

29 ian. 2026, 22:27 UTC

Câștiguri

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29 ian. 2026, 22:27 UTC

Câștiguri

GE Vernova Gains After Earnings. Guidance Boost Was Enough to Lift the Stock. -- Barrons.com

29 ian. 2026, 22:12 UTC

Câștiguri

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29 ian. 2026, 21:55 UTC

Câștiguri

Micron Stock Rises. Samsung Signals a 'Golden Era' for Memory Chips. -- Barrons.com

29 ian. 2026, 21:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

29 ian. 2026, 21:50 UTC

Câștiguri

These Stocks Are Today's Movers: Microsoft, Meta, Tesla, Joby Aviation, SAP, Royal Caribbean, and More -- Barrons.com

29 ian. 2026, 21:50 UTC

Market Talk
Câștiguri

Health Care Roundup: Market Talk

29 ian. 2026, 21:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

29 ian. 2026, 21:49 UTC

Câștiguri

Honeywell Delivers Solid Earnings Ahead of Its Corporate Breakup -- Barrons.com

29 ian. 2026, 21:46 UTC

Câștiguri

Apple Posts Blowout iPhone Sales on Surging China Demand -- Update

29 ian. 2026, 21:36 UTC

Câștiguri

Lockheed Martin Stock Jumps on Guidance and Government Missile Deal -- Barrons.com

29 ian. 2026, 21:32 UTC

Câștiguri

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29 ian. 2026, 21:32 UTC

Câștiguri

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29 ian. 2026, 21:30 UTC

Câștiguri

Apple Posts Blowout IPhone Sales on Surging China Demand -- WSJ

29 ian. 2026, 21:30 UTC

Câștiguri

Apple 1Q Mac Rev $8.39B >AAPL

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

30.52% sus

Prognoză pe 12 luni

Medie 69.63 USD  30.52%

Maxim 105 USD

Minim 40 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

331 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat